Shares of Indivior PLC (NASDAQ:INDV - Get Free Report) have received a consensus recommendation of "Buy" from the seven research firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $45.17.
Several analysts have issued reports on the company. Craig Hallum restated a "buy" rating and set a $53.00 price objective on shares of Indivior in a research note on Tuesday, August 4th. Zacks Research upgraded Indivior from a "hold" rating to a "strong-buy" rating in a research report on Friday, October 2nd. Barclays decreased their price objective on shares of Indivior from $46.00 to $43.00 and set an "overweight" rating for the company in a report on Wednesday, August 5th. Finally, Weiss Ratings downgraded Indivior from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Thursday, September 24th.
Read Our Latest Report on INDV
Indivior Stock Performance
Shares of Indivior stock opened at $34.16 on Thursday. The firm has a market cap of $4.03 billion, a PE ratio of 12.24 and a beta of 0.87. The firm's 50-day simple moving average is $36.13 and its 200-day simple moving average is $36.72. Indivior has a 1 year low of $23.72 and a 1 year high of $42.81.
Indivior (NASDAQ:INDV - Get Free Report) last posted its quarterly earnings results on Tuesday, June 30th. The company reported $5.75 EPS for the quarter. The business had revenue of $343.00 million during the quarter. Indivior had a negative return on equity of 283.11% and a net margin of 26.65%. On average, equities analysts predict that Indivior will post 3.66 earnings per share for the current year.
Indivior Dividend Announcement
The business also recently disclosed a special dividend, which will be paid on Friday, November 6th. Investors of record on Friday, October 30th will be given a dividend of $8.13 per share. The ex-dividend date is Friday, October 30th.
Insider Transactions at Indivior
In related news, CAO Woodrow D. Anderson acquired 1,500 shares of the stock in a transaction that occurred on Thursday, August 27th. The stock was purchased at an average cost of $35.69 per share, for a total transaction of $53,535.00. Following the purchase, the chief accounting officer directly owned 27,638 shares in the company, valued at $986,400.22. This represents a 5.74% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 0.74% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Indivior
Hedge funds have recently added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd grew its position in shares of Indivior by 72.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company's stock worth $39,000 after acquiring an additional 460 shares during the last quarter. Rockefeller Capital Management L.P. increased its holdings in shares of Indivior by 512.4% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,286 shares of the company's stock worth $46,000 after acquiring an additional 1,076 shares during the period. TD Waterhouse Canada Inc. bought a new stake in Indivior in the 2nd quarter valued at about $63,000. GAMMA Investing LLC bought a new stake in Indivior in the 2nd quarter valued at about $66,000. Finally, Farther Finance Advisors LLC lifted its position in Indivior by 716.2% in the 3rd quarter. Farther Finance Advisors LLC now owns 3,624 shares of the company's stock valued at $130,000 after purchasing an additional 3,180 shares during the last quarter. 60.33% of the stock is currently owned by institutional investors.
Indivior Company Profile
(
Get Free Report)
Indivior PLC NASDAQ: INDV is a specialty pharmaceutical company focused on developing and commercializing treatments for substance use disorders and serious mental health conditions. The company's primary focus is opioid use disorder, with products designed to support patients through medication-assisted treatment and recovery.
Indivior's portfolio includes Sublocade, an extended-release injectable formulation of buprenorphine; Suboxone, a buprenorphine and naloxone product available in sublingual formulations; and Perseris, an extended-release injectable formulation of risperidone for schizophrenia.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Indivior, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Indivior wasn't on the list.
While Indivior currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.